ReFacto AF (moroctocog alfa) Prescribing Information for Great Britain click here. ReFacto AF (moroctocog alfa) Prescribing Information for Northern Ireland click here.
Adverse event reporting information can be found at the bottom of the page.
ReFacto AF® (moroctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). ReFacto AF® is appropriate for use in adults and children of all ages, including newborns. ReFacto AF® does not contain von Willebrand factor, and hence is not indicated in von Willebrand's disease.1
The original ReFacto® (moroctocog alfa) was approved in 1999 - the first recombinant factor VIII product licensed for patients with haemophilia A.1
Pfizer continue to invest in the research and development of haemophilia treatment.
ReFacto AF® (moroctocog alfa) contains recombinant coagulation factor VIII, which has functional characteristics comparable to those of endogenous factor VIII.1
The ReFacto AF® manufacturing process is completely albumin-free from cell culture to the end product.10
ReFacto AF® has a well-documented safety profile in adult patients. Paediatric safety profile is comparable to that of adults.1
** This is an optional area where footnotes can live.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021